Presentations and Interviews

’Noterat’ – A business podcast by Dagens Industri [December 01, 2025]

PILA PHARMA CEO Gustav H. Gram introduces the company in the ‘Noterat’ (Listed) podcast released on December 01, 2025! In this in-depth conversation both PILA PHARMA and its oral solution for obesity and type-2 diabetes is discussed as well as the overall obesity market and how PILA PHARMA is a differentiated player in the space.

Link to Apple Podcast: here

Link to Spotify: here

Aktiespararna – Store Aktiedagarana [November 26, 2025]

PILA PHARMA CEO Gustav H. Gram gives a market update investors on the company and the progress of its oral solution for obesity and diabetes.

Link to video here

Business Update – CEO Gustav H. Gram comments new Obesity study agreement with Gubra [October 02, 2025]

Clinical stage biotech company PILA PHARMA has entered into an agreement with the Danish research organisation Gubra to conduct preclinical studies of the their drug candidate, a TRPV1 inhibitor called XEN-D0501, in obesity. The studies aim to show proof-of-concept in obesity rat models and constitute an important step in the company’s development of this innovative treatment as a potential next generation, oral, first-in-class drug candidate. In an interview with Direkt Studios, CEO Gustav H. Gram comments on the significance of the agreement and the next step in the research program.

Link to video here

Oversubscribed to 293,5%! CEO reacts and discusses rights issue outcome with 10X Podcast! [August 29, 2025]

Among other topics the following is discussed: the heavily oversubscribed rights issue (293,5%), How it fuels our aspirations to investigate our proprietary and potential first-in-class TRPV1 inhibitor, in pure obesity studies, The timelines with which investors can expect news. Furthermore its debated how the obesity market is a theme, how it has become a megatrend, with an expected future fragmenting market with emphasis on tablets to address the market volume. Subsequently to conclude how a company like PILA PHARMA‘s and its simple oral alternative solution fits in the big picture

The podcast segment is recorded in English and the segment starts at 29:40
(Link to video) here

SIT-DOWN INTERVIEW WITH FINWIRE TALKING FUNDRAISING AND BET ON OBESITY [July 04, 2025]

CEO Gustav H. Gram begins by introducing the PILA PHARMA ‘oral solution for obesity, a TRPV1-antagonist, a very different target to other drugs in development for obesity and diabetes. He emphasizes how the obesity market has grown tremendously and is increasingly looking to fragment and how oral solutions will be key to address the huge volume of people living with overweight globally.

He also talks about their ongoing rights issue of units, where the company wish to fund dedicated obesity studies in rats and humans living with overweight. With the issue quite remarkably covered by pre-commitments to 99,87%, and why PILA PHARMA may present an attractive opportunity for investors in a market segment with estimates of more than 1 billion people living with obesity and value estimates of more than $100 billion annually by 2030.

Find the link to the video (In English) here

INTERVIEW ON RIGHTS ISSUE AND BET ON OBESITY WITH DIREKT STUDIOS [July 04, 2025]

PILA PHARMA’s CEO Gustav H. Gram discusses the ongoing rights issue together with Mathias Vahlne from Swedish financial media outlet, Direkt Studios, an issue which is which is covered by existing investors and guarantor pre-commitments to 99,87%.

PILA PHARMA wishes to use the proceeds to fund a venture into pure obesity studies with emphasis on achieving a comprehensive and meaningful data package that can facilitate a partnership. The Company’s overall aspirations remain to develop a new oral drug for obesity and diabetes treatment based on TRPV1 inhibition.

Find the link to the video (In English) here

Ongoing rights issue and bet on obesity with investment podcast 10x [July 3, 2025]

CEO Gustav H. Gram shares exciting updates on the company’s rights issue where the share offering, which is already 99% secured, and the proceeds will fuel a new venture in obesity with their promising pill treatment.

Find the link to the video (In English) here

PILA PHARMA aktieemission – næste skridt mod fedmepille [Juni 27, 2025]

“Der er noget helt usædvanligt ved den her kapitalrejsning, og det er jo at den er forhåndsgaranteret til 100%” – Helge Larsen

PILA PHARMA og adm. direktør Gustav Hanghøj Gram har været tilbage hos ProInvestor og snakke om den store tilslutning og opbakning til vores kapitalrejsning der skal finansiere nye dedikerede fedme studier med PILA PHARMA’s tablet baseret på TRPV1 hæmning – en helt ny og anderledes fremgangsmåde!

Find the link to the video (In Danish) here

Pila Pharma visited Direkt Studios’ investment channel [Jun2 16, 2025]

CEO Gustav H. Gram participated in person with Eric Lindeen from Swedish investment media outlet, Nyhetsbyrån Direkt Studios, briefly presenting PILA PHARMA and its differentiated approach to develop a new oral drug for obesity and diabetes treatment.

Find the link to the video (In English) here

Pila Pharma participated in investment podcast 10x [June 11, 2025]

CEO Gustav H. Gram participated in person with Joakim Båge from Swedish investment focused podcast, 10X, discussing both PILA PHARMA and its aspirations to develop a new oral drug for obesity and diabetes treatment.

Find the link to the video (In English) here

Pila Pharma – Ny oral behandling til type 2-diabetes og fedme [Juni 05, 2025]

Fedmemarkedet handler primært om glp1, senere er amylin blevet kendt, men det dansk-svenske biotekselskab Pila Pharma, grundlagt af Dorte X. Gram med rødder i Novo Nordisk, udvikler en oral behandling mod type 2-diabetes og fedme baseret på en såkaldt chili-receptor. Hør mere i denne video, hvor Helge Larsen har besøg af Dorte X. Gram.

Find the link to the video (In Danish) here

PILA PHARMA STOKK.io After-Work Q&A [October 28, 2024]

PILA PHARMA’s CEO, Mr. Gustav H. Gram hosts an investor after-work Q&A specifically tailored with investor questions collected from different Stock trading forums and PILA PHARMA’s social media platforms.

In this session he answers questions from investors that touches upon the status, happenings and other things such as the market and global trends for Diabetes, Obesity and Cardiovascular disease, disease areas that PILA aims to address.

The Q&A was held together with moderator Anders Egsvang Rasmussen from Stokk.io, a platform that facilitates investor reach for companies.

The Q&A is conducted in English here

PILA PHARMA, REDEYE, Cardiovascular & Metabolic day [October 17, 2024]

PILA PHARMA’s CEO, Mr. Gustav H. Gram participates in an online Investor Forum with Redeye and provides an update on the Company’s H1 report, the happenings and expected events for H2, 2024. Furthermore we have a Q&A with Analyst Filip Einarsson, answering investor questions about PILA PHARMA, the market and global trends for Diabetes, Obesity and Cardiovascular disease that PILA aims to tap into.

The presentation & Q&A is conducted (in English) here

PILA PHARMA x REDEYE H1 Report & Q&A [August 29, 2024]

PILA PHARMA’s CEO, Mr. Gustav H. Gram participates in a online Investor Forum with Redeye and provides an update on the Company’s H1 report, the happenings and expected events for H2, 2024. Furthermore we have a Q&A with Analyst Filip Einarsson, answering investor questions about PILA PHARMA, the market and global trends for Diabetes, Obesity and Cardiovasculardisease that PILA aims to tap into.

The presentation & Q&A is conducted (in English) here